Sequence Bio

Founded: 2013 • Age: 13 yrs
Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.
Request Access

About Sequence Bio

Sequence Bio is a company founded in 2013.. Sequence Bio has raised $5.47 million across 4 funding rounds from investors including Y Combinator, DCVC and Killick Capital. Sequence Bio offers products and services including Genetics Platform and Discovery Cohorts. Sequence Bio operates in a competitive market with competitors including Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience, among others.

  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sequence Bio, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $5.47 M (USD)

    in 4 rounds

  • Latest Funding Round
    $1.32 M (USD), Seed

    Jul 30, 2019

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Sequence Bio

Sequence Bio offers a comprehensive portfolio of products and services, including Genetics Platform and Discovery Cohorts. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for systems biology to identify disease signals in genetics.

Service providing powered cohorts for disease research and drug development.

People of Sequence Bio
Headcount 50-200
Employee Profiles 6
Employee Profiles
People
Bari Ballew
Senior Director of Data Science and Analytics
People
Sam Rasty
Chief Executive Officer and Board Director
People
David Phillips
Director of Finance & Administration
People
Meg MacMillan
Computational Biologist

Unlock access to complete

Funding Insights of Sequence Bio

Sequence Bio has successfully raised a total of $5.47M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $1.32 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Seed — $1.3M
  • First Round

    (19 Oct 2015)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2019 Amount Seed - Sequence Bio Valuation

investors

Jun, 2019 Amount Seed - Sequence Bio Valuation Y Combinator
Jun, 2016 Amount Seed - Sequence Bio Valuation DCVC
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Sequence Bio

Sequence Bio has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Y Combinator, DCVC and Killick Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Early-stage startups are accelerated via funding and educational programs.
Founded Year Domain Location
Venture capital firm focused on multiple sectors
Founded Year Domain Location
Killick Capital is engaged in private equity investments in Canada.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Sequence Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Sequence Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sequence Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Sequence Bio

Sequence Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, Novogene Corporation, HitGen, Singular Genomics and Slingshot Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Genome sequencing platform is provided for clinical diagnostics.
domain founded_year HQ Location
Genomic services and solutions with NGS expertise are provided.
domain founded_year HQ Location
DNA-encoded libraries are developed for drug discovery applications.
domain founded_year HQ Location
Next-generation gene sequencing and multi-omics technologies are provided.
domain founded_year HQ Location
Next-generation synthetic cells are developed for diagnostics and therapeutics.
domain founded_year HQ Location
Next-generation sequencing and genomics services are provided globally.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Sequence Bio

When was Sequence Bio founded?

Sequence Bio was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Who is the current CEO of Sequence Bio?

Chris C Gardner is the current CEO of Sequence Bio.

Is Sequence Bio a funded company?

Sequence Bio is a funded company, having raised a total of $5.47M across 4 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Oct 19, 2015.

What does Sequence Bio do?

Sequence Bio was established in 2013 in Newfoundland and Labrador, Canada, as a data-driven biotechnology company. A 100,000-person genome sequencing project is led by the firm to analyze genetic data for medical applications. Operations center on genomic research and data processing to support advancements in disease treatment and pharmaceutical development within the biotechnology sector. The company is headquartered in the region with Chris C. Gardner serving as CEO and President.

Who are the top competitors of Sequence Bio?

Sequence Bio's top competitors include Novogene Corporation, BGI and Singular Genomics.

What products or services does Sequence Bio offer?

Sequence Bio offers Genetics Platform and Discovery Cohorts.

Who are Sequence Bio's investors?

Sequence Bio has 5 investors. Key investors include Y Combinator, DCVC, Killick Capital, Klister Credit, and Pelorus Venture Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available